IL140848A - Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate - Google Patents

Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate

Info

Publication number
IL140848A
IL140848A IL14084899A IL14084899A IL140848A IL 140848 A IL140848 A IL 140848A IL 14084899 A IL14084899 A IL 14084899A IL 14084899 A IL14084899 A IL 14084899A IL 140848 A IL140848 A IL 140848A
Authority
IL
Israel
Prior art keywords
phenylacetylisoglutamine
phenylacetylglutamine
phenylacetate
pharmaceutical compositions
pharmaceutical composition
Prior art date
Application number
IL14084899A
Other languages
English (en)
Other versions
IL140848A0 (en
Original Assignee
Burzynski Stanislaw R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burzynski Stanislaw R filed Critical Burzynski Stanislaw R
Publication of IL140848A0 publication Critical patent/IL140848A0/xx
Publication of IL140848A publication Critical patent/IL140848A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14084899A 1998-07-23 1999-07-02 Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate IL140848A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (2)

Publication Number Publication Date
IL140848A0 IL140848A0 (en) 2002-02-10
IL140848A true IL140848A (en) 2005-05-17

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14084899A IL140848A (en) 1998-07-23 1999-07-02 Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate

Country Status (21)

Country Link
US (2) US6258849B1 (ko)
EP (1) EP1098643B1 (ko)
JP (2) JP2002521329A (ko)
KR (4) KR100417101B1 (ko)
CN (3) CN100400039C (ko)
AT (1) ATE257378T1 (ko)
AU (1) AU759278B2 (ko)
BR (1) BR9912356A (ko)
CA (1) CA2336945C (ko)
DE (1) DE69914084T2 (ko)
DK (1) DK1098643T3 (ko)
EA (1) EA004179B1 (ko)
ES (1) ES2214866T3 (ko)
HK (1) HK1037142A1 (ko)
ID (1) ID28160A (ko)
IL (1) IL140848A (ko)
NZ (1) NZ509244A (ko)
PL (1) PL213698B1 (ko)
PT (1) PT1098643E (ko)
WO (1) WO2000004894A2 (ko)
ZA (1) ZA200100622B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
AU8531101A (en) 2000-08-29 2002-03-13 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
DK1773767T3 (en) * 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
WO2006020403A2 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
ES2537974T3 (es) * 2004-11-26 2015-06-16 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
SG174982A1 (en) 2009-04-03 2011-11-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
WO2012048043A1 (en) 2010-10-06 2012-04-12 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
CA2995823A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JP6861708B2 (ja) * 2015-12-30 2021-04-21 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 除脂肪体重を測定するための方法
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
KR20200024145A (ko) 2017-05-11 2020-03-06 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제조방법
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
EP3638224A4 (en) * 2017-06-12 2021-02-24 BURZYNSKI, Stanislaw R. METHOD OF TREATMENT OF LEPTOMENING DISEASE
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472A (zh) * 2022-12-14 2023-07-28 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
CA2254772C (en) 1996-05-14 2004-01-27 Stanislaw R. Burzynski Liposomal antineoplaston therapies with markedly improved antineoplastic activity

Also Published As

Publication number Publication date
CA2336945A1 (en) 2000-02-03
CN1660061A (zh) 2005-08-31
ATE257378T1 (de) 2004-01-15
IL140848A0 (en) 2002-02-10
KR20030027089A (ko) 2003-04-03
US6943192B2 (en) 2005-09-13
EA004179B1 (ru) 2004-02-26
PT1098643E (pt) 2004-05-31
AU759278B2 (en) 2003-04-10
JP2011051993A (ja) 2011-03-17
BR9912356A (pt) 2001-04-17
CN1191064C (zh) 2005-03-02
PL345959A1 (en) 2002-01-14
PL213698B1 (pl) 2013-04-30
EA200100168A1 (ru) 2001-08-27
EP1098643A2 (en) 2001-05-16
CN100400039C (zh) 2008-07-09
WO2000004894A2 (en) 2000-02-03
DE69914084T2 (de) 2004-10-28
JP2002521329A (ja) 2002-07-16
HK1037142A1 (en) 2002-02-01
DE69914084D1 (de) 2004-02-12
AU4854299A (en) 2000-02-14
CA2336945C (en) 2008-11-18
WO2000004894A3 (en) 2000-04-27
CN1605334A (zh) 2005-04-13
ES2214866T3 (es) 2004-09-16
KR100414587B1 (ko) 2004-01-13
NZ509244A (en) 2004-02-27
DK1098643T3 (da) 2004-05-24
ZA200100622B (en) 2002-06-26
CN1319010A (zh) 2001-10-24
KR100417100B1 (ko) 2004-02-05
KR20030027087A (ko) 2003-04-03
KR20030027088A (ko) 2003-04-03
ID28160A (id) 2001-05-10
US6258849B1 (en) 2001-07-10
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
US20010044466A1 (en) 2001-11-22
EP1098643B1 (en) 2004-01-07
KR100417101B1 (ko) 2004-02-05

Similar Documents

Publication Publication Date Title
IL140848A (en) Pharmaceutical compositions containing phenylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
ATE390414T1 (de) Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
NO20054324L (no) Anvendelse av ranolazin og minst ett pH-avhengig bindemiddel for fremstilling av ranolazinpreparater med depotvirkning
RO116342B1 (ro) Compoziţie farmaceutică lichidă, orală
AU1537095A (en) Therapeutic agents containing thyroid hormones
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
YU54499A (sh) Farmaceutski preparat za primenu na mukozu
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
DE60000288D1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
SE8204873L (sv) Farmaceutiska preparat, innefattande humant insulin och human c-peptid
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
JPS56138110A (en) Suppository containing citric acid or salt thereof
JPS54105221A (en) Preparation of stable concentrated dopa injection
MD457G2 (ro) Derivaţi noi de naftiridină, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizarea lor ca medicamente de antireproducere
KR900017599A (ko) 종양 치료용 약학 조성물
UA30393A (uk) Спосіб лікування коронарного атеросклерозу
JPS5524150A (en) Anti-malignant-tumor agent
JPS5569510A (en) Carcinostatic agent
UA38479A (uk) Спосіб моделювання остеопорозу
SU1744810A1 (ru) Вазоактивное средство, нормализующее функции вегетативной нервной системы "димефосфон"

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired